Caris Life Sciences

Caris Life Sciences Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

03/02/2026

A recent study from the American Cancer Society shows colorectal cancer is now the leading cause of cancer-related deaths in people under the age of 50 in the United States. During , it’s especially important to highlight advancements that can help change this trajectory.

Caris helps physicians make the most informed treatment decisions for patients with metastatic colorectal cancer by using innovative solutions like Caris FOLFIRSTai, an AI-driven molecular predictor of chemotherapy efficacy. Learn more: https://ow.ly/F0Lj50Yo7gW

Caris Life Sciences completed the interim readout of Achieve 1, the study supporting the upcoming launch of Caris Detect...
02/26/2026

Caris Life Sciences completed the interim readout of Achieve 1, the study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test.

This interim readout of Achieve 1 represents a major milestone in Caris’ goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.

“This additional data has allowed us to achieve greater performance metrics than others and shows that methodologies focused on limited biological information are not sufficient to encompass the diversity of molecular aberrations driving cancer, especially in early-stage disease,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences


Learn more: https://ow.ly/e0Ag50YmKrA

Caris Life Sciences reported financial results 2025 Q4 and full year, which included full year revenue growth of 97% dri...
02/26/2026

Caris Life Sciences reported financial results 2025 Q4 and full year, which included full year revenue growth of 97% driven by strong performance in molecular profiling services.

The company expects full-year 2026 revenue to be in the range of $1.0 billion to $1.02 billion

Learn more: https://ow.ly/Ign750YmEQP

Every cancer is different, so is every path to treatment. When Balwinder’s family turned to Caris, biomarker testing rev...
02/25/2026

Every cancer is different, so is every path to treatment. When Balwinder’s family turned to Caris, biomarker testing revealed information that helped her care team make the right decisions.

Learn how testing can support more informed cancer care: https://bit.ly/44CJSL0

Caris Life Sciences announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. Caris re...
02/24/2026

Caris Life Sciences announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. Caris recently added the breast cancer signature for capecitabine to the Caris AI Insights section of the report.

“Caris AI Insights help researchers and clinicians provide a valuable molecular blueprint of a patient’s tumor biology and is another way Caris’ testing goes above and beyond for patients, clinicians and researchers,” said Caris President David Spetzler, MS, PhD, MBA.

Learn more: https://ow.ly/W4lf50YkN20

Caris Life Sciences will participate in the TD Cowen 46th Annual Health Care Conference, which will be held March 2-4, 2...
02/23/2026

Caris Life Sciences will participate in the TD Cowen 46th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts. Learn more: https://ow.ly/wB5U50Yj7wN

Attending the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco? Stop by Booth 73 t...
02/20/2026

Attending the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco? Stop by Booth 73 to meet with our experts and learn what Caris has in store for the future of precision medicine. Learn more: ow.ly/bqiQ50YiRME

02/16/2026

MI Cancer Seek® is the first and only simultaneous WES/WTS-based assay with CDx indications for both adult and pediatric (ages 1-22) patients.

Consult with a healthcare professional about your treatment options. Read more about MI Cancer Seek and explore important product information here: https://bit.ly/4lyGNTR

02/11/2026

Caris Assure is an advanced assay that analyzes over 23,000+ genes at the DNA and RNA level, using whole exome and whole transcriptome sequencing.

This approach offers exceptional accuracy and precision in evaluating crucial molecular features of a patient's cancer.

Find out how Caris has transformed liquid biopsy profiling:
https://bit.ly/4eYqHQO

Caris Life Sciences will report fourth quarter 2025 and full year 2025 financial results on Thursday, February 26, 2026....
02/09/2026

Caris Life Sciences will report fourth quarter 2025 and full year 2025 financial results on Thursday, February 26, 2026. Learn more: https://ow.ly/PG7c50Yascg

Today, Matthew Oberley, MD, PhD, Chief Clinical Officer at Caris Life Sciences, explained how WES-based reporting is exp...
02/05/2026

Today, Matthew Oberley, MD, PhD, Chief Clinical Officer at Caris Life Sciences, explained how WES-based reporting is expanding to include pharmacogenomic and emerging biomarkers and how CHIP-aware liquid biopsy interpretation improves variant confidence during the 2026 Liquid Biopsy for Precision Oncology Summit.

Today is World Cancer Day.We join the global movement to raise awareness about the critical role of cancer research and ...
02/04/2026

Today is World Cancer Day.

We join the global movement to raise awareness about the critical role of cancer research and access to treatment, because every cancer journey is unique, and every patient deserves care tailored to their disease.

At Caris Life Sciences, we are advancing precision medicine to help clinicians make more informed decisions and empower patients around the world to take greater control of their cancer journey.

“World Cancer Day reminds us that every individual’s cancer journey is unique and that uniqueness is our most significant source of insight. At Caris, we are united by a shared commitment to decode the molecular individuality of each patient’s disease. Advances in AI and precision medicine are allowing us to transform those insights into actionable intelligence, giving clinicians the power to make more informed decisions and bringing patients closer to the proper treatment at the right time." - David Spetzler, MS, PhD, MBA, Caris President.

Learn more: https://bit.ly/44Gqugl

Address

-
Irving, TX
75039

Opening Hours

Monday 7am - 7pm
Tuesday 7am - 7pm
Wednesday 7am - 7pm
Thursday 7am - 7pm
Friday 7am - 7pm

Telephone

+18889798669

Website

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

#WeAreCarisLS

We believe in more treatment options. Because more treatment options, can mean more time with the ones you love the most.

We’re dedicated to fulfilling the promise of precision medicine and changing the face of cancer care by providing the personalized and precise information needed to guide individualized treatment options. Learn more about our suite of market-leading molecular profiling offerings that assesses DNA, RNA and proteins to reveal the highest quality molecular blueprint so you can determine treatment options with confidence: www.carismolecularintelligence.com.